Biomarkers of neuroinflammation in patients with chronic cerebral ischemia during the therapy with vinpocetine (study INFLAMARK)

Close metadata

OBJECTIVE

To evaluate the effect of vinpocetine therapy on clinical manifestations of chronic cerebral ischemia (CCI) and the blood concentrations of neuroinflammation markers (S100B, IL-1β).

MATERIAL AND METHODS

The study included 30 patients (mean age 61.6 [56.9; 67.9] years) with CCI that received vinpocetine (30 mg/day) for 3 months. Brain changes according to magnetic resonance imaging data were assessed using the STRIVE protocol. We analyzed the dynamics of changes in the clinical questionnaires: Montreal Cognitive Assessment Scale (MoCA), Hospital Anxiety and Depression Scale (HADS), Asthenic State Scale (ASS), Epworth Sleepiness Scale (ESS), general impressions of treatment (Global Rating of Change Scale, GRC).

RESULTS

In 3 months after vinpocetine therapy there was a significant improvement in cognitive status (MoCA: 25.1±2.1 vs 26.6±1.4 p<0.05), emotional state (HADS: 8.4±1.4 vs 7.1±1.8 (p<0.05)), daytime sleep parameters (ESS 8.4±2.1 vs 6.2±2.3 p<0.05) and reduction in asthenia (ASS: 72.2±18.1 vs 52.3±9.3, p<0.05). A significantly larger proportion of patients assessed the improvement from therapy as «moderate» and «pronounced» (GRC, n=22, 73.3%). Concentrations of S100B and IL-1β decreased significantly by the time therapy was completed. The overall severity of cerebrovascular changes according to MRI was significantly associated with blood levels of S100β, but not IL-1β: β=0.504, p=0.026, 95% CI 0.149—0.901, mainly due to periventricular changes in white matter (β=0.562, p=0.035, 95% CI (–0.024—0.820). Blood levels of S100β correlated with MoCA test results (r=0.6795), and IL-1β correlated with ESS scores (r=0. 6657).

CONCLUSIONS

The use of vinpocetine can significantly reduce the severity of cognitive and affective disorders, asthenia, normalize the circadian rhythm of sleep, suppress the expression S100β and IL-1β in patients with CCI. One of the vinpocetine’s mechanisms of action may be the inhibition of neuroinflammation.

Keywords:

chronic cerebral ischemia

biomarkers

S100β

IL-1β neuroinflammation

vinpocetine

Authors:

Samartcev I.N.

Kirov Military Medical Academy

SPIN RSCI: 9857-4986
Scopus AuthorID: 57218542945
ORCID: 0000-0002-7659-9756

Zhivolupov S.A.

Kirov Military medical academy

ORCID: 0000-0003-0363-102X

Gorbatenkova O.V.

Kirov Military medical academy

ORCID: 0000-0001-6218-2135

Ponomarev V.V.

Belarusian State Medical University

ORCID: 0000-0002-4725-4580

Butakova J.S.

Novodvinsk Central City Hospital

ORCID: 0000-0002-0121-5180

Received:

01.11.2023

Accepted:

02.11.2023

List of references:

Kinney JW, Bemiller SM, Murtishaw AS, et al. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement. 2018;4:575-590. https://doi.org/10.1016/j.trci.2018.06.014
Edison P, Brooks DJ. Role of neuroinflammation in the trajectory of Alzheimer’s disease and in vivo quantification using PET. J Alzheimers Dis. 2018;64:339-351. https://doi.org/10.3233/JAD-179929
Bergsbaken T, Fink SL, Cookson T. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7:99-109. https://doi.org/10.1038/nrmicro2070
Kreisl WC, Kim MJ, Coughlin J, et al. PET imaging of neuroinflammation in neurological disorders. Lancet Neurol. 2020;19(11):940-950. https://doi.org/10.1016/S1474-4422(20)30346-X
Zhao YY, Yu JZ, Li QY, et al. TSPO-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation. Neuron Glia Biol. 2011;7:187-197. https://doi.org/10.1017/S1740925X12000129
Langeh U, Singh S. Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders. Curr Neuropharmacol. 2021;19(2):265-277. https://doi.org/10.2174/1570159X18666200729100427
Lyra e Silva NM, Gonçalves RA, Pascoal TA, et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease. Transl Psychiatry. 2021;11:251-255. https://doi.org/10.1038/s41398-021-01349-z
Baudier J, Mochly-Rosen D, Newton A, et al. Comparison of S100b protein with calmodulin: interactions with melittin and microtubule-associated tau proteins and inhibition of phosphorylation of tau proteins by protein kinase C. Biochemistry. 1987;26(10):2886-2893.
Mendiola AS, Cardona AE. The IL-1β phenomena in neuroinflammatory diseases. J Neural Transm. 2018;125(5):781-795. https://doi.org/10.1007/s00702-017-1732-9
Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007;8:221-232.
Wardlaw JM, Smith EE, Biessels GJ, et al. nEuroimaging STIRVE. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838. https://doi.org/10.1016/S1474-4422(13)70124-8
Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683-1689. https://doi.org/10.1212/wnl.43.9.1683
Doubal FN, MacLullich AM, Ferguson KJ, et al. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke. 2010;41(3):450-454. https://doi.org/10.1161/STROKEAHA.109.564914
Lau KK, Li L, Schulz U, et al. Total small vessel disease score and risk of recurrent stroke: validation in 2 large cohorts. Neurology. 2017;88(24):2260-2267. https://doi.org/10.1212/WNL.0000000000004042
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Morozova MA, Potanin SS, Beniashvili AG, et al. Validation of the Hospital Anxiety and Depression Scale Russian-language version in the general population. Profilakticheskaya Meditsina. 2023;26(4):7-14. (In Russ.). https://doi.org/10.17116/profmed2023260417
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;4:540-545.
Rogov EI. The handbook of a practical psychologist. A study guide. M.: VLADOS; 1999. (In Russ.).
Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1988;10:407-415. https://doi.org/10.1016/0197-2456(89)90005-6
Rebrova OT. Statistichesky analis meditsinskikh dannykh. Primenenije paketa prikladnykh program STATISTICA. M.: MediaSfera; 2002. (In Russ.).
Szatmari S, Whitehouse P. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1):CD003119.
Skoromets AA, Aliev KT, Lalayan TV, et al. Cognitive functions and treatment of their impairment in elderly patients with the vertebrobasilar insufficiency. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(4):18-24. (In Russ.).
Zhivolupov SA, Samartsev IN, Yakovlev EV, et al. The effectiveness of Vinpocetine (Cavinton Comfort) in the treatment of dizziness in patients with dyscirculatory encephalopathy and its effect on the concentration of brain neurotrophic factor (BDNF) in plasma. Klinicheskaya Farmakologiya i Terapiya. 2016;(1):48-53. (In Russ.).
Samartsev IN, Zhivolupov SA, Butakova YuS, et al. Efficiency of long-term vinpocetine administration in the treatment of dizziness and associated statodynamic disorders in patients with chronic cerebrovascular insufficiency (EDELWEISS study). Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):36-47. (In Russ.).
Zhang W, Huang Y, Li Y, et al. Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. Clin Drug Invest. 2016;36:697-704. https://doi.org/10.1007/s40261-016-0415-x
Vas A, Gulyas B, Szabo Z, et al. Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J Neurol Sci. 2002;203-204:259-262. https://doi.org/10.1016/s0022-510x(02)00301-5
Nagel DJ, Aizawa T, Jeon KI, et al. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res. 2006;98(7):777-784. https://doi.org/10.1161/01.RES.0000215576.27615.fd
Jeon KI, Xu X, Aizawa T, et al. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Nat Acad Sci. 2010;107(45):9795-9800.
Ruiz-Miyazawa KW, Pinho-Ribeiro FA, Zarpelon AC, et al. Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-kappaB. Chem Biol Interact. 2015;237(7):9-17. https://doi.org/10.1016/j.cbi.2015.05.007
Liu RT, Wang A, To E, et al. Vinpocetine inhibits amyloid-beta induced activation of NF-kappaB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells. Exp Eye Res. 2014;127(34):49-58. https://doi.org/10.1016/j.exer.2014.07.003
Zhao YY, Yu JZ, Li QY, et al. TSPO-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation. Neuron Glia Biol. 2011;34(7):187-197. https://doi.org/10.1017/S1740925X12000129
Feng X, Wang Y, Hao Y, et al. Vinpocetine inhibited the CpG oligodeoxynucleotide-induced immune response in plasmacytoid dendritic cells. Imm Invest. 2013;46(6):263-273. https://doi.org/10.1080/08820139.2016.1248561
Lam AG, Koppal T, Akama KT, et al. Mechanism of glial activation by S100B: involvement of the transcription factor NFkappaB. Neurobiol Aging. 2001;22(5):765-772. https://doi.org/10.1016/S0197-4580(01)00233-0
Hu J, Castets F, Guevara J, Van Eldik L. S100 stimulates inducible nitric oxide synthase activity, and mRNA levels in rat cortical astrocytes. J Biol Chem. 1996;271(6):2543-2547. https://doi.org/10.1074/jbc.271.5.2543
Gao Q, Fan Y, Mu LY, et al. S100B and ADMA in cerebral small vessel disease and cognitive dysfunction. J Neurol Sci. 2015;354(1-2):27-32. https://doi.org/10.1016/j.jns.2015.04.031
Usmanova DD, Madzhidova EN. Participation of neurospecific protein S100 and myelin basic protein in the pathogenesis of chronic cerebral ischemia. Siberian Medical Review. 2017;8(1):60-63. (In Russ.). https://doi.org/10.20333/2500136-2017-1-60-63
Yamasaki Y, Matsuura N, Shozuhara H, et al. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke. 1995;26(7):676-681. https://doi.org/10.1161/01.STR.26.4.676
Wang H, Chen H, Jin J, et al. Inhibition of the NLRP3 inflammasome reduces brain edema and regulates the distribution of aquaporin-4 after cerebral ischaemia-reperfusion. Life Sci. 2020;251:117638. https://doi.org/10.1016/j.lfs.2020.117638
Li J, Liu Z, Wang L, et al. Thousand and one kinase 1 protects MCAO503 induced cerebral ischemic stroke in rats by decreasing apoptosis and pro-inflammatory factors. Biosci Rep. 2019;39:BSR20190749. https://doi.org/10.1042/BSR20190749
Friedlander RM, Gagliardini V, Hara H, et al. Expression of a Dominant Negative Mutant of Interleukin-1β Converting Enzyme in Transgenic Mice Prevents Neuronal Cell Death Induced by Trophic Factor Withdrawal and Ischemic Brain Injury. J Exp Med. 1997;185:933-940. https://doi.org/10.1084/jem.185.5.933
Ma C, Yang L, Wang L. Correlation of Serum C-Peptide, Soluble Intercellular Adhesion Molecule-1, and NLRP3 Inflammasome-Related Inflammatory Factor Interleukin-1β after Brain Magnetic Resonance Imaging Examination with Cerebral Small Vessel Disease. Contrast Media Mol Imaging. 2022;2022:4379847. https://doi.org/10.1155/2022/4379847
Zhang Y, Li X, Qiao S, et al. Occludin degradation makes brain microvascular endothelial cells more vulnerable to reperfusion injury in vitro. J Neurochem. 2021;156(7):352-366. https://doi.org/10.1111/jnc.15102
Che Mohd Nassir CMN, Damodaran T, Ismail NI, et al. The NLRP3 Inflammasome in Age-Related Cerebral Small Vessel Disease Manifestations: Untying the Innate Immune Response Connection. Life (Basel). 2023;13(1):216. https://doi.org/10.3390/life13010216
Noz MP, Ter Telgte A, Wiegertjes K, et al. Pro-inflammatory Monocyte Phenotype During Acute Progression of Cerebral Small Vessel Disease. Front Cardiovasc Med. 2021;8:639361. https://doi.org/10.3389/fcvm.2021.639361
Tringall G, Dello Russo C, Preziosi P, Navarra P. Interleukin-1 in the central nervous system: From physiology to pathology. Therapie. 2000;55:171-175.
Anisman H, Marali Z. Cytokines, stress and depressive illness: Brain-immune interactions. Ann Med. 2003;35(5):2-11.
Jewett KA, Krueger JM. Humoral sleep regulation; interleukin-1 and tumor necrosis factor. Vitam Horm. 2012;89(12):241-257. https://doi.org/10.1016/B978-0-12-394623-2.00013-5
Samartcev IN, Zhivolupov SA, Efimtsev AYu, Ponomarev VV. Analysis of the correlation between neuroimaging markers of the brain damage and the severity of postural instability in patients with chronic cerebrovascular insufficiency (NEMAN open observational study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(7):66-73. (In Russ.). https://doi.org/10.17116/jnevro202212207166

Close metadata